Company profile
Doseology Sciences Inc.
OTC: DOSEF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Kelowna, BCReports USD
#1114 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
40DFH 44DQ —GM 40SS 17
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$58.6k
Rev growth YoY (TTM)
+75.7%
Net income (FY)
-$235.7k
Employees
3
as of 2026-08-27
Market cap
$501.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$22.4k31.3k CAD2025
Net income-$235.7k-328.9k CAD2025
Operating income-$248.2k-346.4k CAD2025
Total assets$803.1k1.1M CAD2025
Liabilities$69.0k94.1k CAD2025
Equity$1.0M1.4M CAD2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Doseology Sciences Inc.’s revenue?
Doseology Sciences Inc. booked $22.4k in FY2025 revenue, contracting 69% year over year — slower than 86% of Healthcare companies we track, at a -1052.2% net margin.
Peers · Healthcare
Talphera, Inc.46DProteonomix, Inc.——Sirona Biochem Corp.——Senti Biosciences, Inc.27DJupiter Neurosciences, Inc.18DSkinvisible, Inc.29DKey facts
CEOChristopher Jackson
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersKelowna, BC
ExchangeOTC: DOSEF
Employees3
IPO date2022-05-11
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.